Categories
Business
After 27 Years, Cytokinetics Has a Product on the Market
On December 19, 2025, the FDA cleared MYQORZO, the brand name for aficamten, a cardiac myosin inhibitor for adults with symptomatic obstructive hypertrophic cardiomyopathy. For Cytokinetics, a South San Francisco biotech founded…
Read More